

The image is a promotional graphic for SecurAcath. At the top, the brand name 'SecurAcath' is written in a bold, black, sans-serif font, with a stylized orange 'A' that has a downward-pointing arrow. Below the name, on the left side, are two lines of white text: 'Reduce Infections' and 'Decrease Dislodgements'. Underneath this text is a white link 'Learn More' followed by a right-pointing arrow. On the right side of the graphic, there is a close-up photograph of the SecurAcath device, which is a yellow, wedge-shaped catheter with a central needle. The device has 'LIFT' and 'HOLD' labels on its sides and the SecurAcath logo on top. The background of the graphic is a gradient of orange and brown, with a white diagonal line separating the top text area from the bottom image area.

Reduce Infections

Decrease Dislodgements

Learn More ►



Although oxaliplatin (Oxali) plays a key role in the treatment of many types of cancer and has been reported to be an irritant, there is no specific and effective method for its extravasation and failure in Oxali extravasation management results in the need for plastic surgery” Bahadori and Demiray (2018).

Abstract:

Although oxaliplatin (Oxali) plays a key role in the treatment of many types of cancer and has been reported to be an irritant, there is no specific and effective method for its extravasation and failure in Oxali extravasation management results in the need for plastic surgery. In the

body, Oxali bio-transforms upon dilution in chloride-containing buffer salts to its di-chloro derivative and loses an oxalate molecule. Consequently, the chloride ions exchange with water molecules in the intracellular environment to produce the di-aqua derivative, which is the most active biotransformation product of Oxali in terms of forming the DNA adducts. Thus, inhibiting transformation of di-chloro to di-aqua derivatives by accumulating chloride ions at the site of extravasation and saturating the Oxali molecule with these ions is a strategy that could help manage extravasation. Injecting normal saline at this site is a simple yet effective way to achieve this goal.

Reference:

Bahadori, F. and Demiray, M. (2018) Management of extravasation of oxaliplatin by mimicking its biotransformation. *Clinical & Translational Oncology*. April 27th. .

doi: 10.1007/s12094-018-1854-z.

